首页>
外国专利>
Indication of phytotherapeutic medicine clinically extrau00ecdo of Artemisia artemisifolia, hatusima. For the human infection by Toxoplasma gondii
Indication of phytotherapeutic medicine clinically extrau00ecdo of Artemisia artemisifolia, hatusima. For the human infection by Toxoplasma gondii
Clinical indication of medicine herbal medicine extracted from Artemisia artemisifolia, hatusima. For the human infection by Toxoplasma gondii.Invention patent for the treatment of toxoplasmosis by referring to a second use (clinical indication) of the drug artesunate originally extracted from Artemisia Anua Swiss, imported and distributed in the country under the trade name plasmotrin 32, used for the treatment of Malaria. Its prescription in Brazil is restricted to the endemic regions of North and North East.The drugs used in the treatment of toxoplasmosis have no action on the cyst and no indication for the chronic phase of the infection, i.e., there is no treatment during the latent phase of the parasite.The treatment is considered standard for toxopjasmose adquinda is the combination of pyrimethamine and sulphonamides act synergistic way on the metabolism of phallic acid, acting on the proliferative forms of Toxo plasma gondu.However, due to its toxicity and therapeutic efficacy of this combination may be severely limited, as these drugs cause side effects expressive (Lescano et al, 2004).It is expected with the experimental and clinical studies of the artesu NATO, extracted from Artemisia AI temisifolia of Amazonian origin, the perception of the mechanism of action of compound herbal medicine in bradizou00edtos and taquizoitos,Latent forms of parasite and proliferative as the reference drug is expected to reduce the toxicity in individuals imunossupnmidos or sensitivity to a given medication and also in children and pregnant women, after the marketing of the product.
展开▼
机译：从蒿蒿中提取的草药的临床指征。用于弓形虫的人类感染。治疗弓形虫病的发明专利，是指第二种用途（临床指称）青蒿琥酯药物的第二次使用（临床指征），最初从Artemisia Anua Swiss提取，然后在该国进口并以商品名plasmotrin <32出售，用于治疗疟疾。它在巴西的处方仅限于北部和东北部的流行地区。用于治疗弓形虫病的药物对囊肿没有作用，也没有迹象表明感染的慢性期，即在潜伏期不进行治疗该方法被认为是弓形螨病的标准治疗方法，是乙胺嘧啶和磺胺类药物联合作用于阳具的新陈代谢，作用于弓形虫血浆中的增生形式，但是由于其毒性和治疗功效这种组合可能会受到严重限制，因为这些药物会引起副作用的表达（Lescano等人，2004年）。预期对Artesu NATO的实验和临床研究（取自亚马逊血统的Artemisia AI temisifolia）及其机理的认识复方脚多酚和taquizoitos中复方草药的作用，作为参考药物的潜在形式的寄生虫和增生药降低产品上市后对个体免疫原性的毒性或对特定药物的敏感性以及对儿童和孕妇的毒性。
展开▼
